Clinic for Endocrinology, Diabetes and Metabolism and Department of Biomedicine, University Hospital of Basel, Basel, Switzerland.
Br J Clin Pharmacol. 2013 Aug;76(2):263-8. doi: 10.1111/j.1365-2125.2012.04297.x.
Metabolic diseases are associated with activation of the innate immune system in various tissues and characterized by elevated inflammatory factors and the presence of immune cells. Type 2 diabetes develops when islet beta cells are deficient in producing sufficient insulin to overcome peripheral insulin resistance. Intra-islet IL-1β activity diminishes beta cell function and survival and governs islet inflammation. Targeting the IL-1 system with the IL-1 receptor antagonist IL1Ra improved insulin secretion, glycaemia and reduced systemic inflammation in a proof of concept study with patients with type 2 diabetes. Currently, long lasting and specific IL-1β blocking antibodies are being evaluated in clinical trials and this may lead to a novel cytokine-based treatment for type 2 diabetes.
代谢性疾病与各种组织中先天免疫系统的激活有关，其特征是炎症因子升高和免疫细胞存在。当胰岛β细胞产生的胰岛素不足以克服外周胰岛素抵抗时，就会发生 2 型糖尿病。胰岛内 IL-1β 的活性降低了β细胞的功能和存活，并控制着胰岛炎症。在一项针对 2 型糖尿病患者的概念验证研究中，用白细胞介素 1 受体拮抗剂 IL1Ra 靶向白细胞介素 1 系统，改善了胰岛素分泌、血糖水平，并降低了全身炎症。目前，长效和特异性的 IL-1β 阻断抗体正在临床试验中进行评估，这可能为 2 型糖尿病提供一种新的基于细胞因子的治疗方法。
